1. Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapy
- Author
-
Raisuke Iijima, Masahide Tokue, Nobutaka Ikeda, Ryo Fukui, Masato Nakamura, Norihiro Kougame, Fumiyuki Hayashi, Mami Watanabe, Hidehiko Hara, Hiroki Takenaka, and Tsuyoshi Ono
- Subjects
medicine.medical_specialty ,animal structures ,business.industry ,medicine.medical_treatment ,Drug-Eluting Stents ,Hemorrhage ,030204 cardiovascular system & hematology ,Surgery ,Clinical trial ,03 medical and health sciences ,Bleeding complication ,0302 clinical medicine ,Japan ,Drug-eluting stent ,Internal medicine ,Cardiology ,Humans ,Medicine ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Intensive care medicine ,Platelet Aggregation Inhibitors ,Event risk - Abstract
At present, there is consensus that prolonged dual antiplatelet therapy (DAPT) is effective to reduce cardiovascular events at the expense of bleeding complication events. A causal relationship of prolonged DAPT with an increase in mortality remains debatable, however, it appears to be obvious that bleeding complications are associated with an increase in cardiac events. Thus, individualized optimal DAPT duration balancing the risk and benefit of DAPT should be applied. In addition, strategy to minimize bleeding complications is highly recommended. Several risk scores have been reported to discriminate the risk and benefits of DAPT. However, in general, bleeding risk and event risk are correlated with each other, thus predictability of these scores is limited to moderate. Therefore, interpretation of previous trials is important to overcome the shortcome in outcomes. In this review, we provide an overview of DAPT trials and clarify the shortfalls to consider in Japan. Finally, possible future trends with reference to the results of recent clinical trials will be presented.
- Published
- 2017
- Full Text
- View/download PDF